Fervent Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 17 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.70 M
- Revenue Growth -0.41%
- Profit Growth -62.65%
- Ebitda 172.96%
- Net Worth 1.06%
- Total Assets -9.57%
About Fervent Life Sciences
Fervent Life Sciences Private Limited (FLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 December 2007 and has a history of 17 years and two months. Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹0.70 M.
Chandrakumar Madhavan, Palaniappan Kaliyaperumal, Lakshmipathi Balasubramani, and One other member serve as directors at the Company.
Company Details
-
Location
Chennai, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U52310TN2007PTC065647
-
Company No.
065647
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
06 Dec 2007
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Fervent Life Sciences?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Palaniappan Kaliyaperumal
|
Director | 06-Dec-2007 | Current |
|
Chandrakumar Madhavan
|
Director | 06-Dec-2007 | Current |
|
Lakshmipathi Balasubramani
|
Director | 30-Sep-2020 | Current |
| Palaniappan Chitra | Additional Director | 06-Jan-2023 | Current |
Financial Performance of Fervent Life Sciences.
Fervent Life Sciences Private Limited, for the financial year ended 2021, experienced Minor drop in revenue, with a 0.41% decrease. The company also saw a substantial fall in profitability, with a 62.65% decrease in profit. The company's net worth moved up by a moderate rise of 1.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Fervent Life Sciences?
In 2021, Fervent Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.70 M
₹0
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 0.07 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Jun 2022 | Axis Bank Limited | ₹0.70 M | Open |
How Many Employees Work at Fervent Life Sciences?
Fervent Life Sciences has a workforce of 13 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Fervent Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fervent Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
